The Administration & Analysis Core C will continuously identify and accomplish administrative tasks relatedto the P01, provide timely biostatistical consultations and uniform analyses to all research projects andcores, and facilitate the communication and dissemination of research data among the investigators. P01leadership will use Core C to facilitate the oversight of the research projects and cores. Core C will ensureeffective and rapid communication and cooperation among investigators, projects, and cores. This core willalso assist in sharing our research data with other investigators both within and outside of Memorial Sloan-Kettering Cancer Center (MSK). The Administration & Analysis Core C will provide: (1) administrative,editorial, and academic services; regulatory and reporting services, including preparation of annual reportsand renewals, to all investigators; (2) communication and sharing of biostatistical methodologies andresearch results with other MSK research groups (in cooperation with the Information Engineering Core B);(3) rapid consultations and consistent biostatistical analyses for similar data sets and operations acrosscores and projects; (4) budget management; and (5) support of the oversight activities of the Executive andScientific Advisory committees. The Administration & Analysis Core C centralizes, expands, and improvesthe operational capabilities of all the individual research projects and cores, avoids duplication, and ensuresoptimum utilization of resources. The MSK Lung P01 Administrator supported by this Core will meet weeklywith the Principal Investigator and monthly with the Executive Committee to assist them in monitoring thestatus of operations so that the research supported by the grant proceeds as rapidly and efficiently aspossible. The MSK Lung P01 Administrator, working with the Principal Investigator and Co-PrincipalInvestigator, will prepare and distribute a yearly progress report for the Executive and the Internal andExternal Scientific Advisory Committees to assist in their annual review and oversight. The Administration &Analysis Core A supports the Principal Investigator, Executive Committee, Advisory Committees, researchprojects and other cores; and provides services that are essential for the P01 to function as an integratedresearch program to develop new targets for treatment in persons with adenocarcinoma of the lung.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA129243-01
Application #
7315939
Study Section
Special Emphasis Panel (ZCA1-GRB-P (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-07-23
Budget End
2008-06-30
Support Year
1
Fiscal Year
2007
Total Cost
$342,114
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661
Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340
Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902

Showing the most recent 10 out of 188 publications